Ultrasound contrast developer ImaRx Pharmaceutical of Tucson hassigned a licensing agreement with Du Pont Merck for its MRX-115Aerosomes agent. The second-generation agent is targeted at cardiacand blood pool imaging and began phase-II clinical trials
Ultrasound contrast developer ImaRx Pharmaceutical of Tucson hassigned a licensing agreement with Du Pont Merck for its MRX-115Aerosomes agent. The second-generation agent is targeted at cardiacand blood pool imaging and began phase-II clinical trials lastmonth. Du Pont Merck will assume clinical development of cardiologyand radiology applications for MRX-115 after ImaRx finishes phase-IItrials.
Du Pont Merck will make up-front, milestone and royalty paymentsto ImaRx in exchange for exclusive rights to MRX-115 for cardiologyand radiology applications in North and South America, and forcardiology applications in the European Union. ImaRx retains rightsto the agent for radiology applications in the European Union,and all rights in other regions of the world.
ImaRx is developing several other contrast agents, includingLumenHance, a gastrointestinal MRI agent, and SonoRx, a gastrointestinalultrasound agent (SCAN 3/10/93).
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.